[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"home-modules":3,"home-news-preview":121,"home-clinical-assets":142},{"module9":4,"module8":25,"module7":34,"module6":43,"module5":63,"module4":73,"module3":96,"module2":102,"intro":112},{"id":5,"type":6,"title":7,"subtitle":8,"description":9,"imageUrl":10,"videoLink":10,"videoCover":10,"buttonText":10,"buttonLink":10,"sort":11,"status":12,"features":13},9,"module9","RenSuper Membership Plans","\u003Cp>\u003Cbr>\u003C\u002Fp>","\u003Cp>Flexible membership plans for antibody data, library access, and advanced antibody design tools.\u003C\u002Fp>","",0,1,[14,19],{"id":15,"moduleId":5,"title":16,"subtitle":17,"description":18,"imageUrl":10,"sort":12},210,"Basic Membership","Free","\u003Cp>Ideal for individual researchers looking to explore our target and PCC libraries with essential data insights.\u003C\u002Fp>",{"id":20,"moduleId":5,"title":21,"subtitle":22,"description":23,"imageUrl":10,"sort":24},211,"Professional Membership","Contact Sales","\u003Cp>Designed for professionals who require full data access, antibody design tools, and collaborative workflow features.\u003C\u002Fp>",2,{"id":26,"type":27,"title":10,"subtitle":28,"description":8,"imageUrl":10,"videoLink":29,"videoCover":30,"buttonText":10,"buttonLink":10,"sort":11,"status":12,"features":31},8,"module8","\u003Cp>See How RenSuper\u003C\u002Fp>\u003Cp>Antibody Design Platform Works\u003C\u002Fp>","https:\u002F\u002Fbiocytogen-no2.oss-cn-beijing.aliyuncs.com\u002Fdc1c924b48cf42f7a1fe911fa9b71d53.mp4","https:\u002F\u002Fbiocytogen-no2.oss-cn-beijing.aliyuncs.com\u002Ff887d3b7ea74409b9e9d94f428d79a59.png",[32],{"id":33,"moduleId":26,"title":10,"subtitle":10,"description":8,"imageUrl":10,"sort":12},184,{"id":35,"type":36,"title":37,"subtitle":8,"description":38,"imageUrl":39,"videoLink":10,"videoCover":10,"buttonText":10,"buttonLink":10,"sort":11,"status":12,"features":40},7,"module7","All Binder Types","\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0)\">Biocytogen's comprehensive, fully human antibody portfolio spans diverse binder formats. We support a wide range of discovery needs—from high-affinity monoclonals and plug-and-play bispecific formats to compact VHH molecules with deep tissue penetration, as well as antibodies targeting hard-to-drug GPCRs and other challenging targets.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>","https:\u002F\u002Fbiocytogen-no2.oss-cn-beijing.aliyuncs.com\u002F20260127\u002FAll-Binder-Types_1769482852242.png",[41],{"id":42,"moduleId":35,"title":10,"subtitle":10,"description":8,"imageUrl":10,"sort":12},149,{"id":44,"type":45,"title":46,"subtitle":8,"description":47,"imageUrl":48,"videoLink":10,"videoCover":10,"buttonText":10,"buttonLink":10,"sort":11,"status":12,"features":49},6,"module6","Full Target Library","\u003Cp>Built on the proprietary RenMice\u003Csup>®\u003C\u002Fsup> platform, Biocytogen's antibody library offers access to 1,000+ druggable targets and over one million experimentally validated, fully human antibody sequences, providing partners with a highly reliable and efficient source of discovery-ready molecules.\u003C\u002Fp>\u003Cp>This comprehensive library supports the development of diverse therapeutic modalities—including bispecific antibodies, multispecific antibodies, ADCs, VHHs, oligonucleotide-based therapies, and cell therapies—with broad applications across oncology, autoimmune, metabolic, and neurological diseases.\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>","https:\u002F\u002Fbiocytogen-no2.oss-cn-beijing.aliyuncs.com\u002F42563e1cb94c41d19a05e5610f549a09.png",[50,54,58],{"id":51,"moduleId":44,"title":52,"subtitle":53,"description":8,"imageUrl":10,"sort":12},157,"1000+","Druggable Targets",{"id":55,"moduleId":44,"title":56,"subtitle":57,"description":10,"imageUrl":10,"sort":24},158,"1M+","Fully Human Antibody Sequences",{"id":59,"moduleId":44,"title":60,"subtitle":61,"description":10,"imageUrl":10,"sort":62},159,"280+","Partnerships",3,{"id":64,"type":65,"title":66,"subtitle":67,"description":68,"imageUrl":69,"videoLink":10,"videoCover":10,"buttonText":10,"buttonLink":10,"sort":11,"status":12,"features":70},5,"module5","questions or inquiries?","\u003Ch3>Contact Us\u003C\u002Fh3>","\u003Cp>\u003Cspan style=\"color: rgb(81, 81, 108);background-color: rgb(255, 255, 255)\">We work closely with leading biotech and pharmaceutical companies around the world to advance cutting-edge drug discovery programs. Share your inquiry here—we'll be in touch soon.\u003C\u002Fspan>\u003C\u002Fp>","https:\u002F\u002Fbiocytogen-no2.oss-cn-beijing.aliyuncs.com\u002F20251204\u002Fbox4-logo1_1764815193433.png",[71],{"id":72,"moduleId":64,"title":10,"subtitle":10,"description":8,"imageUrl":10,"sort":12},88,{"id":74,"type":75,"title":76,"subtitle":77,"description":8,"imageUrl":10,"videoLink":29,"videoCover":78,"buttonText":10,"buttonLink":10,"sort":11,"status":12,"features":79},4,"module4","Antibody Design","\u003Cp>How to Design Antibodies with RenSuper Workstation\u003C\u002Fp>","https:\u002F\u002Fbiocytogen-no2.oss-cn-beijing.aliyuncs.com\u002F25de66bd08e04118b3e39243a1060b00.jpg",[80,84,88,92],{"id":81,"moduleId":74,"title":10,"subtitle":82,"description":8,"imageUrl":83,"sort":12},186,"\u002Fantibody-design","https:\u002F\u002Fbiocytogen-no2.oss-cn-beijing.aliyuncs.com\u002F20260114\u002FFrame 1160449460 (1)_1768399355761.png",{"id":85,"moduleId":74,"title":10,"subtitle":10,"description":86,"imageUrl":87,"sort":24},187,"\u003Cp>RenSuper supports drag-and-assemble design of flexible antibody formats, including monoclonal, bispecific, multispecific, VHH, and TCR constructs.\u003C\u002Fp>","https:\u002F\u002Fbiocytogen-no2.oss-cn-beijing.aliyuncs.com\u002F20251204\u002Fbox3-icon1_1764814985892.png",{"id":89,"moduleId":74,"title":10,"subtitle":10,"description":90,"imageUrl":91,"sort":62},188,"\u003Cp>Choose from a million-scale library of fully human binder sequences covering 1,000+ targets to build your next antibody therapeutic.\u003C\u002Fp>","https:\u002F\u002Fbiocytogen-no2.oss-cn-beijing.aliyuncs.com\u002F20251204\u002Fbox3-icon2_1764815008529.png",{"id":93,"moduleId":74,"title":10,"subtitle":10,"description":94,"imageUrl":95,"sort":74},189,"\u003Cp>Built-in affinity and functionality analysis ensures the selection of high-confidence designs.\u003C\u002Fp>","https:\u002F\u002Fbiocytogen-no2.oss-cn-beijing.aliyuncs.com\u002F20251204\u002Fbox3-icon3_1764815025540.png",{"id":62,"type":97,"title":10,"subtitle":98,"description":8,"imageUrl":10,"videoLink":10,"videoCover":10,"buttonText":10,"buttonLink":10,"sort":11,"status":12,"features":99},"module3","\u003Cp>\u003Cstrong>RenSuper Antibody Design Workstation\u003C\u002Fstrong> is a \u003C\u002Fp>\u003Cp>digitalized and automated platform enabling \u003C\u002Fp>\u003Cp>multi-format, fully human antibody \u003Cimg src=\"https:\u002F\u002Fbiocytogen-no2.oss-cn-beijing.aliyuncs.com\u002Ff1c99bb9d22d42b993798744be6dd916.png\" alt=\"Frame 15323.png\" data-href=\"https:\u002F\u002Fbiocytogen-no2.oss-cn-beijing.aliyuncs.com\u002Ff1c99bb9d22d42b993798744be6dd916.png\" style=\"width: 43.00px;height: 43.00px;\"> discovery.\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>Powered by an advanced \u003Cimg src=\"https:\u002F\u002Fbiocytogen-no2.oss-cn-beijing.aliyuncs.com\u002Feae5f6f83a14471893b05971fb959eca.png\" alt=\"Frame 15323 (1).png\" data-href=\"https:\u002F\u002Fbiocytogen-no2.oss-cn-beijing.aliyuncs.com\u002Feae5f6f83a14471893b05971fb959eca.png\"> AI model trained on 100M+ fully human \u003C\u002Fp>\u003Cp>antibody sequences, the RenSuper Workstation reduces antibody design \u003C\u002Fp>\u003Cp>timelines from years to hours—eliminating the need for repetitive animal \u003C\u002Fp>\u003Cp>immunization and CRO outsourcing.\u003C\u002Fp>",[100],{"id":101,"moduleId":62,"title":10,"subtitle":10,"description":8,"imageUrl":10,"sort":12},213,{"id":24,"type":103,"title":104,"subtitle":105,"description":106,"imageUrl":10,"videoLink":10,"videoCover":10,"buttonText":107,"buttonLink":10,"sort":11,"status":12,"features":108},"module2","Antibody-based Assets","\u003Cp>Preclinical Candidate Portfolio\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>","\u003Cp>Biocytogen's RenMab\u003Csup>®\u003C\u002Fsup>, RenLite\u003Csup>®\u003C\u002Fsup>, and RenNano\u003Csup>®\u003C\u002Fsup> platforms power the generation of fully human monoclonal, bispecific, and hu-VHH antibodies with strong therapeutic potential.\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>Through these platforms, we offer a diverse and expanding portfolio of preclinical candidate (PCC) molecules to meet the evolving drug development needs of our partners.\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>","Search Products",[109],{"id":110,"moduleId":24,"title":111,"subtitle":10,"description":8,"imageUrl":10,"sort":12},185,"标题1",{"id":12,"type":113,"title":10,"subtitle":114,"description":115,"imageUrl":116,"videoLink":10,"videoCover":10,"buttonText":10,"buttonLink":117,"sort":11,"status":12,"features":118},"intro","\u003Cp>Powered by our proprietary RenMice\u003Csup>®\u003C\u002Fsup> platforms, Biocytogen provides an off-the-shelf library of 1M+ fully human antibody sequences spanning 1,000+ targets—ready for rapid drug discovery\u003C\u002Fp>","\u003Cp>SEARCH FOR THE RENSUPER BIOLOGICS LIBRARY\u003C\u002Fp>","https:\u002F\u002Fbiocytogen-no2.oss-cn-beijing.aliyuncs.com\u002F20251209\u002Fbanner-title_1765243432546.png","http:\u002F\u002Fadmin-dev.biocytogen.com.cn\u002Fconfig\u002Findex-module",[119],{"id":120,"moduleId":12,"title":10,"subtitle":10,"description":8,"imageUrl":10,"sort":12},172,[122,129,136],{"id":123,"publishTime":124,"type":125,"newsGroup":125,"title":126,"detailContent":127,"relatedImportTaskId":128},37,1775959219613,"TARGET_LIBRARY","Target Library Expanded with Metabolic Targets","The preclinical candidate compound (Target) library has been updated with 4257 new metabolic disease candidates, including detailed MOA summaries and early-stage validation data. Updated at 2026-04-12 10:00:19.",178,{"id":130,"publishTime":131,"type":132,"newsGroup":132,"title":133,"detailContent":134,"relatedImportTaskId":135},32,1775722706860,"PCC_LIBRARY","PCC Library Expanded with Metabolic Targets","The preclinical candidate compound (PCC) library has been updated with 68 new metabolic disease candidates, including detailed MOA summaries and early-stage validation data. Updated at 2026-04-09 16:18:26.",171,{"id":137,"publishTime":138,"type":139,"newsGroup":139,"title":140,"detailContent":141,"relatedImportTaskId":51},25,1771205112886,"BINDER_LIBRARY","New Antibody Binder Sequences Added","Over 33 newly validated antibody binder sequences have been added to the RenSuper library, covering oncology and autoimmune targets. Users can now explore expanded binding diversity and affinity profiles. Updated at 2026-02-16 09:25:12.",{"list":143,"total":217,"pageNo":12,"pageSize":218},[144,160,166,171,179,182,189,195,199,202,207,211],{"id":145,"therapeuticArea":146,"productNumber":147,"targets":148,"format":149,"monoComboTherapy":150,"indication":151,"devStage":152,"country":153,"progressPercentage":154,"partner":155,"pdfUrl":156,"pdfName":157,"jumpAddress":158,"collected":159},1120,"Oncology","BCG008","SIGLEC15","mAb","Mono","Solid tumors","Phase I","China","50%","Partnered","https:\u002F\u002Fbiocytogen-no2.oss-cn-beijing.aliyuncs.com\u002F849b19dba0fa47a09b7f114f6957b12a.pdf","SIGLEC15 Monoclonal Antibody (BCG008).pdf",null,false,{"id":161,"therapeuticArea":146,"productNumber":162,"targets":163,"format":164,"monoComboTherapy":150,"indication":151,"devStage":152,"country":165,"progressPercentage":154,"partner":155,"pdfUrl":158,"pdfName":158,"jumpAddress":158,"collected":159},1117,"BCG011\u002FDM001","TACSTD2,EGFR","BsADC","Global MRCT",{"id":167,"therapeuticArea":146,"productNumber":168,"targets":169,"format":164,"monoComboTherapy":150,"indication":151,"devStage":170,"country":165,"progressPercentage":154,"partner":155,"pdfUrl":158,"pdfName":158,"jumpAddress":158,"collected":159},1119,"BCG012\u002FDM002","ERBB3,MUC1","Phase II",{"id":172,"therapeuticArea":146,"productNumber":173,"targets":174,"format":149,"monoComboTherapy":175,"indication":151,"devStage":152,"country":176,"progressPercentage":177,"partner":178,"pdfUrl":10,"pdfName":10,"jumpAddress":158,"collected":159},1110,"YH001","CTLA4","PD-1","Australia","100%","Partnered ex-China\nrights available",{"id":180,"therapeuticArea":146,"productNumber":173,"targets":174,"format":149,"monoComboTherapy":150,"indication":181,"devStage":152,"country":153,"progressPercentage":177,"partner":155,"pdfUrl":158,"pdfName":158,"jumpAddress":158,"collected":159},1111,"Solid tumors",{"id":183,"therapeuticArea":146,"productNumber":184,"targets":185,"format":149,"monoComboTherapy":186,"indication":187,"devStage":170,"country":188,"progressPercentage":154,"partner":155,"pdfUrl":10,"pdfName":10,"jumpAddress":158,"collected":159},1112,"YH002","TNFRSF4","YH003+YH001","Intratumoral injection","Investigator Initiated Trials",{"id":190,"therapeuticArea":146,"productNumber":191,"targets":192,"format":149,"monoComboTherapy":193,"indication":181,"devStage":152,"country":165,"progressPercentage":194,"partner":155,"pdfUrl":158,"pdfName":158,"jumpAddress":158,"collected":159},1115,"YH003","CD40","PD-1+YH001","80%",{"id":196,"therapeuticArea":146,"productNumber":191,"targets":192,"format":149,"monoComboTherapy":197,"indication":198,"devStage":170,"country":165,"progressPercentage":177,"partner":155,"pdfUrl":158,"pdfName":158,"jumpAddress":158,"collected":159},1113,"PD-1+chemo","Pancreatic ductal adenocarcinoma (1L&2L)",{"id":200,"therapeuticArea":146,"productNumber":191,"targets":192,"format":149,"monoComboTherapy":197,"indication":201,"devStage":170,"country":153,"progressPercentage":154,"partner":155,"pdfUrl":158,"pdfName":158,"jumpAddress":158,"collected":159},1114,"Mucosal melanoma",{"id":203,"therapeuticArea":146,"productNumber":204,"targets":205,"format":206,"monoComboTherapy":150,"indication":151,"devStage":152,"country":153,"progressPercentage":177,"partner":155,"pdfUrl":158,"pdfName":158,"jumpAddress":158,"collected":159},1116,"YH008","PDCD1,CD40","BsAb",{"id":208,"therapeuticArea":146,"productNumber":209,"targets":210,"format":164,"monoComboTherapy":150,"indication":151,"devStage":152,"country":165,"progressPercentage":154,"partner":155,"pdfUrl":158,"pdfName":158,"jumpAddress":158,"collected":159},1118,"YH013\u002FDM005","EGFR,MET",{"id":212,"therapeuticArea":213,"productNumber":214,"targets":215,"format":149,"monoComboTherapy":150,"indication":216,"devStage":152,"country":153,"progressPercentage":154,"partner":155,"pdfUrl":158,"pdfName":158,"jumpAddress":158,"collected":159},1121,"Rare Diseases","BCG009","IGF1R","Rare Disease",12,20]